

REMARKS

This amendment is being submitted prior to fee calculation to resolve multiple dependencies in claims 4, 5, 6, 10, 12, 13, 15, 16, and 17. No prohibited new matter has been introduced.

Applicants reserve the right to present the canceled subject matter later during prosecution of the subject application or any related application.

CONCLUSIONS

In view of the foregoing amendments and discussion, examination of the subject application is respectfully requested. Should the Examiner have any questions relating to this amendment to the application in general, the Examiner is invited to contact Applicants' undersigned representative.

If there are any other fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. Except for issue fees payable under 37 CFR §1.18, the commissioner is hereby authorized by this paper to charge any additional fees during the pendency of this application including fees due under 37 CFR §1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 CFR §1.136(a)(3).

Respectfully Submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: June 30, 2003

By: Bonnie Weiss McLeod
Bonnie Weiss McLeod
Reg. No. 43,255

MORGAN, LEWIS & BOCKIUS LLP

1111 Pennsylvania Ave., N.W.

Washington, D.C. 20004

202-739-3000 (Phone)

202-739-3001 (Fax)

APPENDIX

4. A process as claimed in [any one of the preceding claims] claim 1 wherein the material is selected from the group consisting of : polystyrene; polypropylene; polyvinylchloride; nylon; polyester; cotton; a metal; carbon; glass; silica; nitrocellulose; and latex.

5. A process as claimed in [any one of the preceding claims] claim 1 wherein the second protein has a molecular weight of at least 3000 or 5000 Daltons.

6. A process as claimed in [any one of the preceding claims] claim 1 wherein the second protein is catalytically inactive.

10. An immunoadsorbant material obtainable by the process of [any one of claims 1 to 7] claim 1.

12. An immunoadsorbant material as claimed [in claim 10 or claim 11] in claim 10 which constitutes all or part of: a microtitre plate; a flask; an immunoaffinity column; a polymeric beads; a dipstick.

13. Use of a material as claimed [in any one of claims 10 to 12] in claim 10 in an *in vitro* immunological recognition process.

15. Use as claimed in [claim 13 or claim 14] claim 13, wherein the immunological recognition process is an enzyme linked immuno-specific assay procedure (ELISA).

16 Use of a material as claimed in [any one of claims 10 to 12] claim 10, in a purification procedure.

17. A diagnostic test kit comprising a material as claimed in [any one of claims 10 to 12] claim 10.